Sunday, September 27, 2026

NeuroMetrix Stock Over 15% Down In The Last 5 Sessions

NeuroMetrix Stock Over 15% Down In The Last 5 Sessions

(VIANEWS) - Shares of NeuroMetrix (NASDAQ: NURO) fell by a staggering 15.47% in 5 sessions from $1.81 to $1.53 at 14:24 EST on Friday, after two sequential sessions in a row of losses. NASDAQ is sliding 1.26% to $11,196.00, following the last session's downward trend.

NeuroMetrix's last close was $1.63, 72.33% below its 52-week high of $5.89.

About NeuroMetrix

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.47%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.7%, now sitting on 8.23M for the twelve trailing months.

Moving Average

NeuroMetrix's value is way under its 50-day moving average of $1.71 and way under its 200-day moving average of $2.63.

Volatility

NeuroMetrix's last week, last month's, and last quarter's current intraday variation average was a positive 0.89%, a negative 0.19%, and a positive 2.68%.

NeuroMetrix's highest amplitude of average volatility was 1.44% (last week), 2.46% (last month), and 2.68% (last quarter).

Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $1.53 at 14:24 EST, way below its 52-week high of $5.89 and way higher than its 52-week low of $1.33.

More news about NeuroMetrix (NURO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com